• MDxHealth reported peer-reviewed publication of the Oxford GPS-ProMPT study in European Urology Oncology; results were presented in the journal publication.
• The study supported GPS mdx as a tool to identify patients likely to do well long term across common localized prostate cancer management approaches.
• Management framed the publication as scientific groundwork for the ongoing GPS-ProtecT randomized controlled trial, aimed at strengthening evidence for adoption and coverage.

Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. MDxHealth SA published the original content used to generate this news brief on June 29, 2026, and is solely responsible for the information contained therein.